Evidence map›Paper›PMID 23766771›Full record

ArticleStem cells international2013

Human cardiospheres as a source of multipotent stem and progenitor cells.

Lucio Barile, Mihaela Gherghiceanu, Laurenţiu M Popescu, Tiziano Moccetti, Giuseppe Vassalli

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Stem cell therapy for single ventricle congenital heart disease - current state and future directions.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2022
    Review
  5. Review
  6. Article
  7. Cardiac Progenitor Cells.Advances in experimental medicine and biology · 2021
    Review
  8. Article
  9. Review
  10. Notch pathway activation enhances cardiosphere in vitro expansion.Journal of cellular and molecular medicine · 2018
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Cardiovascular Bio-Engineering: Current State of the Art.Journal of cardiovascular translational research · 2017
    Review
  16. Review
  17. Review
  18. A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Article
  19. Arrhythmia in stem cell transplantation.Cardiac electrophysiology clinics · 2015
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Lucio BarileMolecular Cardiology Laboratory and Department of Cardiology, Fondazione Cardiocentro Ticino, Via Tesserete 48, 6900 Lugano, Switzerland.
Mihaela Gherghiceanu
Laurenţiu M Popescu
Tiziano Moccetti
Giuseppe Vassalli
Epatocentro Ticino · CHInstitutul National Victor Babes · ROUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiospheres (CSs) are self-assembling multicellular clusters from the cellular outgrowth from cardiac explants cultured in nonadhesive substrates. They contain a core of primitive, proliferating cells, and an outer layer of mesenchymal/stromal cells and differentiating cells that express cardiomyocyte proteins and connexin 43. Because CSs contain both primitive cells and committed progenitors for the three major cell types present in the heart, that is, cardiomyocytes, endothelial cells, and smooth muscle cells, and because they are derived from percutaneous endomyocardial biopsies, they represent an attractive cell source for cardiac regeneration. In preclinical studies, CS-derived cells (CDCs) delivered to infarcted hearts resulted in improved cardiac function. CDCs have been tested safely in an initial phase-1 clinical trial in patients after myocardial infarction. Whether or not CDCs are superior to purified populations, for example, c-kit(+) cardiac stem cells, or to gene therapy approaches for cardiac regeneration remains to be evaluated.

Identifiers

PMID23766771
PMCPMC3666231
OpenAlexW1992452402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.